SARTORIUS AG-VORZUG (SRT3.DE) Fundamental Analysis & Valuation

FRA:SRT3 • DE0007165631

217.2 EUR
-8.1 (-3.6%)
Last: Mar 6, 2026, 05:36 PM

This SRT3.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, SRT3 scores 2 out of 10 in our fundamental rating. SRT3 was compared to 18 industry peers in the Life Sciences Tools & Services industry. SRT3 may be in some trouble as it scores bad on both profitability and health. SRT3 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. SRT3.DE Profitability Analysis

1.1 Basic Checks

  • In the past year SRT3 was profitable.
  • SRT3 had a positive operating cash flow in the past year.
  • SRT3 had positive earnings in 4 of the past 5 years.
  • SRT3 had a positive operating cash flow in 4 of the past 5 years.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • SRT3 has a Return On Assets of 1.39%. This is in the lower half of the industry: SRT3 underperforms 77.78% of its industry peers.
  • SRT3 has a Return On Equity of 5.01%. This is in the lower half of the industry: SRT3 underperforms 72.22% of its industry peers.
  • With a Return On Invested Capital value of 4.71%, SRT3 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • Measured over the past 3 years, the Average Return On Invested Capital for SRT3 is in line with the industry average of 9.64%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • SRT3's Profit Margin of 3.80% is on the low side compared to the rest of the industry. SRT3 is outperformed by 77.78% of its industry peers.
  • In the last couple of years the Profit Margin of SRT3 has declined.
  • SRT3 has a Operating Margin (14.06%) which is in line with its industry peers.
  • SRT3's Operating Margin has declined in the last couple of years.
  • SRT3's Gross Margin of 46.48% is fine compared to the rest of the industry. SRT3 outperforms 66.67% of its industry peers.
  • In the last couple of years the Gross Margin of SRT3 has declined.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1

2. SRT3.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT3 is still creating some value.
  • SRT3 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • SRT3 has an Altman-Z score of 2.32. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • SRT3's Altman-Z score of 2.32 is in line compared to the rest of the industry. SRT3 outperforms 44.44% of its industry peers.
  • The Debt to FCF ratio of SRT3 is 8.92, which is on the high side as it means it would take SRT3, 8.92 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 8.92, SRT3 is doing worse than 66.67% of the companies in the same industry.
  • SRT3 has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
  • SRT3 has a Debt to Equity ratio of 1.28. This is in the lower half of the industry: SRT3 underperforms 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.32
ROIC/WACC0.57
WACC8.31%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
  • SRT3's Current ratio of 0.95 is on the low side compared to the rest of the industry. SRT3 is outperformed by 83.33% of its industry peers.
  • A Quick Ratio of 0.49 indicates that SRT3 may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.49, SRT3 is doing worse than 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

3

3. SRT3.DE Growth Analysis

3.1 Past

  • Measured over the past 5 years, SRT3 shows a small growth in Earnings Per Share. The EPS has been growing by 1.76% on average per year.
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%

3.2 Future

  • SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.97% yearly.
  • Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.68% on average per year.
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

1

4. SRT3.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 45.44 indicates a quite expensive valuation of SRT3.
  • 83.33% of the companies in the same industry are cheaper than SRT3, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (26.69), we can say SRT3 is valued expensively.
  • Based on the Price/Forward Earnings ratio of 35.90, the valuation of SRT3 can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 77.78% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.79. SRT3 is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 45.44
Fwd PE 35.9
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • SRT3's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. SRT3 is more expensive than 61.11% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as SRT3.
Industry RankSector Rank
P/FCF 33.98
EV/EBITDA 22.39
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • SRT3's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as SRT3's earnings are expected to grow with 20.79% in the coming years.
PEG (NY)1.71
PEG (5Y)25.77
EPS Next 2Y23.47%
EPS Next 3Y20.79%

4

5. SRT3.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.38%, SRT3 is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.44, SRT3 pays a bit more dividend than its industry peers.
  • With a Dividend Yield of 0.38, SRT3 pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.38%

5.2 History

  • The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 37.92% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
  • The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP37.92%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

SRT3.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS AG-VORZUG

FRA:SRT3 (3/6/2026, 5:36:15 PM)

217.2

-8.1 (-3.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.26B
Revenue(TTM)N/A
Net Income(TTM)133.70M
Analysts80
Price Target376.45 (73.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.38%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.73%
PT rev (3m)9.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-0.03%
Valuation
Industry RankSector Rank
PE 45.44
Fwd PE 35.9
P/S 4.62
P/FCF 33.98
P/OCF 18.6
P/B 6.1
P/tB N/A
EV/EBITDA 22.39
EPS(TTM)4.78
EY2.2%
EPS(NY)6.05
Fwd EY2.79%
FCF(TTM)6.39
FCFY2.94%
OCF(TTM)11.68
OCFY5.38%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)1.71
PEG (5Y)25.77
Graham Number61.91
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.32
F-Score7
WACC8.31%
ROIC/WACC0.57
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.23%
EBIT Next 3Y36.56%
EBIT Next 5Y25.33%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 45.44 and the Price/Book (PB) ratio is 6.1.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.